Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vanda Pharmaceuticals Inc. Director's Dealing 2009

Nov 10, 2009

33390_dirs_2009-11-10_df35aef0-56f7-4deb-9622-2e1cff23d25d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2009-11-06

Reporting Person: Feeney John Joseph (Acting Chief Medical Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2009-11-06 Common Stock M 9583 $8.73 Acquired 9583 Direct
2009-11-06 Common Stock M 572 $5.76 Acquired 10155 Direct
2009-11-06 Common Stock M 4062 $1.02 Acquired 14217 Direct
2009-11-06 Common Stock S 14217 $10.3263 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2009-11-06 Employee Stock Option (right to buy) $8.73 M 9583 Disposed 2017-11-28 Common Stock (9583) Direct
2009-11-06 Employee Stock Option (right to buy) $5.76 M 572 Disposed 2018-01-03 Common Stock (572) Direct
2009-11-06 Employee Stock Option (right to buy) $1.02 M 4062 Disposed 2018-09-18 Common Stock (4062) Direct

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $10.26 to $10.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: The option represents a right to purchase a total of 20,000 shares. 25% of the shares subject to the option became exercisable on November 14, 2008 with the remaining shares becoming exercisable in 36 equal monthly installments thereafter.

F3: The option represents a right to purchase a total of 1,250 shares. The option vests in 48 equal monthly installments beginning on February 4, 2008.

F4: The option represents a right to purchase a total of 15,000 shares. 25% of the shares subject to the option became exercisable on September 19, 2009 with the remaining shares becoming exercisable in 36 equal monthly installments thereafter.